Through a comprehensive consultation, we assess your unique needs and medical history to determine if Semaglutide or Tirzepatide are the right choices for you
It does not affect blood glucose levels and is preferable to NSAIDs for many patients, particularly those with cardiovascular risk factors or kidney disease, which are common comorbidities in diabetes
Partial hypoparathyroidism associated with mitochondrial trifunctional protein deficiency
Pharmacy teams should rely on program requirements and prescriber documentation rather than determining eligibility at the pharmacy counter Key details Program timeframe: July 1, 2026, through December 31, 2027 Eligible population: Medicare Part D beneficiaries enrolled in an eligible prescription drug plan who meet CMS eligibility criteria, including the programs clinical requirements for weight management
Consult your GP before stopping Ozempic to discuss alternative diabetes management strategies, monitor blood glucose levels during the transition, and manage any side effects safely
The decision to use Wegovy for IBS management requires careful consideration of its potential benefits against documented risks and side effects
